Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy
- PMID: 8648775
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy
Abstract
Purpose: Up to 26% of patients with pathologically organ confined prostate cancer will experience clinical progression after radical prostatectomy. We attempted to identify patients at greatest risk for future clinical failure despite a favorable pathological outcome.
Materials and methods: The study group included 904 patients treated with bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for disease confined to the prostate gland. Preoperative serum prostate specific antigen (PSA), clinical stage, pathological grade and stage, and deoxyribonucleic acid (DNA) ploidy were evaluated by multivariate analysis to determine relative value in predicting treatment failure. A prognostic scoring system was created using the regression coefficients from the Cox multivariate model to classify patients further according to risk of progression.
Results: Preoperative PSA concentration, clinical stage, grade and DNA ploidy were significant univariate predictors of progression (p < 0.0001), whereas pathological stage was not (p = 0.2). Multivariate analysis identified pathological grade (p < 0.0001), preoperative serum PSA concentration (p = 0.0006) and DNA ploidy (p = 0.0089) as independent predictors of progression. The prognostic scoring system separated the patients into 5 distinct groups. Patients with the lowest score had a 92% progression-free survival rate at 5 years, compared to only 39% of those with the highest scores.
Conclusions: Patients believed to be at higher risk for cancer progression despite having organ confined disease might be targeted for adjuvant therapy and closer surveillance, while those at low risk may be followed less often.
Comment in
-
Prostate cancer--the added factors.J Urol. 1996 Jul;156(1):144-5. doi: 10.1016/s0022-5347(01)65968-8. J Urol. 1996. PMID: 8648776 No abstract available.
-
Re: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.J Urol. 1997 Jan;157(1):270. doi: 10.1016/s0022-5347(01)65356-4. J Urol. 1997. PMID: 8976277 No abstract available.
Similar articles
-
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.J Urol. 1999 Mar;161(3):857-62; discussion 862-3. J Urol. 1999. PMID: 10022701
-
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.J Urol. 2001 Jan;165(1):119-25. doi: 10.1097/00005392-200101000-00030. J Urol. 2001. PMID: 11125379
-
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.J Urol. 2002 Jan;167(1):117-22. J Urol. 2002. PMID: 11743287
-
Risk factors for progression in patients with prostate cancer treated with radical prostatectomy.Semin Urol Oncol. 1996 May;14(2 Suppl 2):12-20; discussion 21. Semin Urol Oncol. 1996. PMID: 8725887 Review.
-
Current prognostic factors for prostate carcinoma.Cancer. 1996 Jul 15;78(2):341-4. doi: 10.1002/(SICI)1097-0142(19960715)78:2<341::AID-CNCR24>3.0.CO;2-V. Cancer. 1996. PMID: 8674014 Review.
Cited by
-
Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.World J Urol. 1997;15(6):339-45. doi: 10.1007/BF01300181. World J Urol. 1997. PMID: 9436283 Clinical Trial.
-
Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer.Biomark Res. 2023 Jun 6;11(1):60. doi: 10.1186/s40364-023-00504-6. Biomark Res. 2023. PMID: 37280670 Free PMC article. Review.
-
How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome.Turk J Urol. 2017 Dec;43(4):456-461. doi: 10.5152/tud.2017.60251. Epub 2017 Dec 1. Turk J Urol. 2017. PMID: 29201508 Free PMC article.
-
Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy.Rev Urol. 2002 Summer;4(3):141-6. Rev Urol. 2002. PMID: 16985669 Free PMC article.
-
Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.Am J Surg Pathol. 2014 Mar;38(3):333-8. doi: 10.1097/PAS.0000000000000162. Am J Surg Pathol. 2014. PMID: 24525503 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous